110 EAST 59TH STREET, NEW YORK, NY
Reports Q4 and Full Year 2025 Results
FDA Approves MYQORZO for Treatment of Obstructive Hypertrophic Cardiomyopathy
Executive Transition - George W. Lloyd to Step Down as Chief Legal Officer
Reports Third Quarter 2025 Results
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Henry Fernandez Steps Down From Board Of Directors
Reports Second Quarter 2025 Results
Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Merger Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
13F Holdings Report - Notice
Free Writing Prospectus
Automatic Shelf Registration Statement